Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.

Date publication

janvier 2015

Journal

BJU international

Auteurs

Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe

Tous les auteurs :
Joly F, Delva R, Mourey L, Sevin E, Bompas E, Vedrine L, Ravaud A, Eymard JC, Tubiana-Mathieu N, Linassier C, Houede N, Guillot A, Ringensen F, Cojocarasu O, Valenza B, Leconte A, Lheureux S, Clarisse B, Oudard S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/24180479

Résumé

To evaluate the overall benefits of non-taxane chemotherapies in a non-selected population including unfit patients presenting with symptoms and pain.

Mots clés

Age Factors, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Etoposide, administration & dosage, Humans, Male, Middle Aged, Mitoxantrone, administration & dosage, Neoplasm Metastasis, Palliative Care, Prednisone, administration & dosage, Prostatic Neoplasms, Castration-Resistant, drug therapy, Taxoids, administration & dosage, Vinblastine, administration & dosage

Référence

BJU Int.. 2015 Jan;115(1):65-73